Many stock analysts see Indianapolis-based Elevance’s recent struggles as an opportunity. Thirteen of 24 analysts tracked by The Wall Street Journal rate the health insurer as a buy.

Artisan Partners, an investment management company, released its “Artisan Select Equity Fund” fourth quarter 2024 investor ...

Elevance Health, Inc. (ELV), with a market ... the past six months and 24.2% over the past 52 weeks. Nevertheless, Wall Street analysts remain strongly bullish on ELV’s prospects.

Elevance Health, Inc. (ELV), with a market cap of $89.92 billion, is a leading health benefits company in the United States.

As Wall Street’s broader market averages continue ... No. 9: Bristol-Myers Squibb (BMY), +5.8% YTD. No. 8: Elevance Health (ELV), +7.2% YTD. No. 7: Altria Group (MO), +9.6% YTD.

Special Needs Plans boosted a sluggish Medicare Advantage market during the annual enrollment period for 2025, a Modern ...

Evolent Health faces volatility with missed targets and 2024 guidance cuts. Click here for a full investment analysis of EVH stock.

Elevance Health has struggled, with shares dropping 30% from its 52-week high and 21.3% over the past year. The managed care sector faces rising medical costs and reimbursement rate misalignments, ...

February 11, 2025 Wall Street ends higher on AI strength ... investor concerns with better-than-feared quarterly profit Elevance Health on Thursday posted a better-than-feared fourth-quarter ...